Abstract
As a member of the Roche Group, Chugai has rights to develop and market all
pharmaceutical products which the Roche Group decides to commercialise in
Japan. This report provides a full review of the company's activities together
with sales forecasts for key products to 2010.
Chugai Pharmaceutical's net sales for 2005 were ¥327,200 million, an 11%
increase over 2004. Operating income was up by 54% to ¥79,200 million, due to
product sales increases and cost saving measures. Net income rose by 57% to
¥53,600 million, due mostly to extraordinary gains from milestone income from
Roche related to co-development of Actemra.
Chugai's reliance on the tough Japanese market has led to a range of
initiatives for overseas expansion. It is building an independent development
and sales infrastructure in Europe and other overseas markets and formulating
a marketing strategy that will establish an autonomous marketing network in
the US.
R&D Pipeline Overview
- Antevas has been filed for the treatment of disorders caused by
acute cerebrovascular diseases.
- ED-71 is an oral vitamin D3 derivative in Phase III trials for the
treatment of osteoporosis.
- VAL has completed Phase II trials in Japan for use in
post-hepatectomy/liver transplantation.
- CHS13340, a nasal spray formulation of recombinant human
parathyroid hormone, has been licensed from Daiichi Suntory Pharma, and is in
Phase II trials for osteoporosis.
- Tarceva is expected to be filed for non-small cell lung cancer in
the first half of 2006.
Major Products Forecast to 2010
- Rythmodan (Cardiovascular)
- Alfurol (Bone Metabolism)
- Epogin (Haematological)
- Neutrogin/Granocyte (Haematological)
- Sigmart/Ikorel (Cardiovascular)
- Rituxan (Anticancer)
- Tamiflu (Antiviral)
| 
View Cart
